TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review published in Science examines whether drugs such as semaglutide and tirzepatide could help preserve memory and other cognitive abilities. Animal findings and patient-record studies offer clues, but human evidence is mixed, and semaglutide did not slow early Alzheimer’s progression in the EVOKE and EVOKE+ trials. Researchers say dedicated trials are needed.
A review published in Science examines whether obesity medicines including semaglutide and tirzepatide could help protect memory and other cognitive abilities, but the evidence in people remains mixed. The researchers say clinical trials should test cognitive outcomes directly, rather than treating possible brain effects as established benefits.
The review was prepared at the invitation of Science by researchers at the University of Gothenburg and the University of Copenhagen. It considers how drugs used for obesity and type 2 diabetes may influence biological processes relevant to brain function. The authors say animal studies indicate that GLP-1 drugs can affect learning and memory, while findings from human research are less consistent.
Some studies using patient records have associated GLP-1 treatment with a lower risk of dementia among people with type 2 diabetes. Those observational findings cannot show that the medicines caused the difference: other health or patient factors may help explain the association. The review also notes that Novo Nordisk’s EVOKE and EVOKE+ clinical trials found semaglutide did not slow disease progression in people with early Alzheimer’s disease, despite changes in several biological markers.
That result does not settle whether the medicines could benefit other groups or affect different aspects of cognition. The authors point to attention, planning and processing speed as abilities that can be affected in people with obesity or type 2 diabetes. They say these difficulties are often linked to metabolic and vascular health, which could make them relevant targets for treatment research.
Testing Cognition Beyond Alzheimer’s
The question matters because cognitive difficulties can affect daily life for people with obesity or type 2 diabetes, while medicines for these conditions are already in use. If future trials show that treatment helps preserve cognitive abilities, that could influence how researchers assess the drugs and which patients might benefit. At present, however, the review describes a research possibility, not a proven brain-protection effect or a reason to use these medicines specifically for memory.
Researchers also need to distinguish whether any cognitive changes come from improved metabolism, direct effects on the brain, or both. That distinction could guide development of treatments designed specifically to preserve cognition, rather than assuming that effects seen with existing obesity medicines explain how the brain responds.
Popular right now
De'Longhi All-in-One Espresso and Coffee Maker with 10-Cup Pot and Milk Frother
TCL 75-Inch QM6K QLED Mini LED 4K HDR Smart Google TV, 144Hz
Dyson R3 Nurovi Spot+Scrub UV Robot Vacuum
As an affiliate, we earn on qualifying purchases.
Evidence From Records to Trials
GLP-1 medicines such as semaglutide and tirzepatide are used to treat obesity and type 2 diabetes. Their effects extend to biological systems that researchers consider relevant to brain function, prompting interest in possible effects on cognition. The review brings together evidence from animal research, analyses of patient records and clinical trials, but these forms of evidence answer different questions.
Animal studies can identify possible biological effects, but do not establish that people will experience the same cognitive outcomes. Patient-record studies can reveal associations across large groups, but cannot by themselves determine cause. The EVOKE and EVOKE+ findings provide evidence from trials in early Alzheimer’s disease, but they do not answer every question about cognition in people with obesity or diabetes who do not have established Alzheimer’s.
“By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function.”
— Christoffer Clemmensen, senior author of the review and research group leader at the University of Copenhagen
Which Patients Might Benefit?
It is not yet clear whether obesity medicines preserve cognition in people with obesity or type 2 diabetes, whether any effect would depend on starting treatment before difficulties appear, or which patients might benefit. The human evidence described in the review is not conclusive, and the patient-record associations do not prove that GLP-1 drugs lower dementia risk.
It is also unknown how much any possible effect would come from changes in metabolism versus a direct action on the brain. The negative result in the EVOKE and EVOKE+ trials applies to slowing progression in early Alzheimer’s disease; it does not establish an effect, positive or negative, for every other patient group or cognitive outcome.
The review also flags possible risks for older or frail patients. Rapid weight loss and loss of muscle mass could harm physical function and reduce potential benefits. The source material does not give a quantified estimate of those risks in this setting.
Trials Must Track Cognitive Change
The researchers are calling for clinical trials that measure memory and other cognitive abilities from the start of treatment. Such studies could compare changes over time and help determine whether any effect differs by patient group or by when treatment begins. They would also help distinguish cognitive outcomes from biological markers that may change without a corresponding improvement in disease progression.
The review authors also emphasize monitoring older and frail patients for rapid weight loss, muscle loss and effects on physical function. Until direct evidence from suitable trials is available, whether these drugs can preserve cognition remains an open research question. Patients should discuss decisions about obesity or diabetes treatment with a qualified health professional; the review does not establish these medicines as treatments for memory problems.
Key Questions
Do obesity drugs protect memory?
That has not been established. The review describes possible effects and calls for trials that directly measure memory and other cognitive abilities in people taking the medicines.
What did the Alzheimer’s trials find?
Novo Nordisk’s EVOKE and EVOKE+ trials found that semaglutide did not slow disease progression in people with early Alzheimer’s disease, although several biological markers changed.
Why are patient-record studies not enough to prove a benefit?
They found an association between GLP-1 treatment and lower dementia risk among people with type 2 diabetes, but records alone cannot establish that the drugs caused the difference or rule out other explanations.
What research do the review authors want?
They call for clinical trials that track memory and other cognitive skills from treatment onset, and for careful monitoring of older and frail patients for rapid weight and muscle loss.
Source: news-medical.net
